Entero Healthcar Q1 FY27 Results (NSE: ENTERO)

· Analysis by Alpha Inflection

Signal: Growth decelerated

The read

The trajectory strengthened at the operating level: consolidated revenue accelerated to +38.2% YoY from +25.6% in Q3FY26 and +42.6% in Q4FY26 remained elevated, while EBITDA margin reached 5.2% versus the recent 4% series; however, finance costs rose 93.1% YoY and ₹13.89 Cr of PAT accrued to non-controlling interests, so group growth is increasingly acquisition-led and must convert into owner earnings.

Entero Healthcar Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹194.05 Cr+38.2%+1.6%
EBIT₹8.77 CrN/A
Net profit₹3.82 Cr+37.3%
EPS₹8.77+37.3%
EBIT margin5.2%

P&L walk

Consolidated revenue rose to ₹1940.5 Cr, +38.2% YoY and +1.6% QoQ, while EBITDA reached ₹100 Cr and EBITDA margin was 5.2%; PAT attributable to owners increased to ₹38.16 Cr, +37.3% YoY, but ₹13.89 Cr was attributable to non-controlling interests.

Segments

The group operates as one reportable pharmaceutical and surgical-products segment, but the consolidated-versus-standalone gap is material: consolidated revenue was ₹1940.5 Cr and owner PAT ₹38.16 Cr versus standalone revenue of ₹83.27 Cr and PAT of ₹3.46 Cr, confirming that earnings are generated predominantly by subsidiaries.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.